Ibutamoren

This page shows anti-doping rule violation data we have registered for Ibutamoren.

Number of cases in Ibutamoren Last 10 Years

Ibutamoren

Ibutamoren ranks #73 globally among prohibited substances, with 38 registered cases (0.3% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,670 verified cases. USA leads with 7 cases, while Weightlifting is the most affected sport (9 cases).

Cases of Ibutamoren by Sport
Weightlifting
9
Powerlifting
7
Rugby
4
Track and field
3
Cycling
3
Top Sport: Weightlifting

9

Weightlifting cases

0%

Of all violations

38

Total Ibutamoren cases
Weightlifting's share of Ibutamoren violations 0%
9 of 38

Weightlifting has the most recorded cases of Ibutamoren violations globally, with 9 registered cases — 0% of all 38 verified cases.

Cases of Ibutamoren by Country
USA
7
Russia
4
South Africa
3
Canada
3
Czech Republic
2
Top Country: USA

7

USA cases

18.4%

Of all violations

38

Total Ibutamoren cases
USA's share of Ibutamoren violations 18.4%
7 of 38

USA leads in Ibutamoren violations globally, with 7 registered cases — 18.4% of all 38 verified cases.

Global Substance Ranking

Ibutamoren ranks #73 of 358 prohibited substances in the Anti-Doping Database.

#1 Stanozolol
1,359
#2 Methandienone
833
#3 Norandrosterone
778
#4 Testosterone
758
···
#73 Ibutamoren
38
About This Ranking

This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.

Active Sanctions — Expiry Year
Gender Distribution
Male 86.8%
33 cases
Female 13.2%
5 cases
Analysis: has a notably higher proportion of male cases (86.8%) compared to the global average (80.2%), a difference of 6.6 percentage points. Global average: 80.2% male, 19.8% female
Average Suspension Length
44.4
months
Ibutamoren
30.1
months
Global average

The average suspension for Ibutamoren violations is 44.4 months, longer than the global average of 30.1 months.

Ibutamoren (or Nutrobal) is a non-peptidic, potent, long-acting, orally-active, and selective agonist of the ghrelin receptor and a growth hormone secretagogue, mimicking the growth hormone (GH)-stimulating action of the endogenous hormone ghrelin. The substance is an orally administrated growth hormone secretagogue originally developed by Reverse Pharmacology. Developmental code names are MK-677, MK-0677, L-163,191. A secretagogue is the term for a substance that chemically signals for the pituitary gland to secrete growth hormone. In other words, Nutrobal could be compared to peptides like GHRP-6 or Ipamorelin, only it doesn’t require any injections nor does it have any side effects like GHRP-6. This GHS (Growth Hormone Secretagogue) was developed in an aim to combat such conditions as muscle wasting, obesity and osteoporosis. It was also targeted towards treatment of elderly hip fracture patients.

If you use this data, please credit The Anti-Doping Database

The intelligence tool for anti-doping professionals

Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.

 

As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:

  • Complete athlete and sanction details
    • Identity, ban periods, substances used, test type, violation information and more.
  • Verified documents and case materials
    • Access sanction decisions, PDFs and official sources when available.
  • Advanced insights and historical trends
    • Statistics across sports, countries, substances and year-by-year comparisons — for proactive planning, not just post-case analysis.

The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.